BioStock: Celebrating IND approval Abliva eyes next step with KL1333

The reporting season is in full swing and Swedish biotech Abliva recently published their fourth quarter results for 2021. Looking at the activities in the last quarter, the company focused on lead candidate KL1333 as it took a pivotal step towards the planned phase II/III-study by obtaining Investigational New Drug-approval from the FDA. BioStock spoke to CEO Ellen Donnelly about the past quarter and what lies ahead.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/celebrating-ind-approval-abliva-eyes-next-step-with-kl1333/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se